AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
AngioDynamics (NASDAQ: ANGO) reported its Q3 FY2025 financial results with pro forma net sales of $72.0 million, up 9.2% year-over-year. The company's MedTech segment showed strong performance with $31.3 million in sales, growing 22.2%, while MedDevice sales reached $40.7 million, up 0.9%.
Key highlights include GAAP gross margin of 54.0%, a loss per share of $(0.11), and adjusted EBITDA of $1.3 million. The company received FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation and initiated the AMBITION BTK trial for the Auryon Atherectomy System.
AngioDynamics increased its FY2025 guidance, now expecting net sales of $285-288 million, MedTech sales growth of 14-16%, gross margin of 53-54%, and adjusted EBITDA of $4.0-5.0 million. The company secured a $25.0 million revolving credit line with J.P. Morgan for additional financial flexibility.
AngioDynamics (NASDAQ: ANGO) ha riportato i risultati finanziari del terzo trimestre dell'anno fiscale 2025 con vendite nette pro forma di 72,0 milioni di dollari, in aumento del 9,2% rispetto all'anno precedente. Il segmento MedTech dell'azienda ha mostrato una forte performance con vendite di 31,3 milioni di dollari, in crescita del 22,2%, mentre le vendite di MedDevice hanno raggiunto 40,7 milioni di dollari, in aumento dello 0,9%.
I punti salienti includono un margine lordo GAAP del 54,0%, una perdita per azione di $(0,11) e un EBITDA rettificato di 1,3 milioni di dollari. L'azienda ha ricevuto l'approvazione FDA 510(k) per il sistema NanoKnife per l'ablazione del tessuto prostatico e ha avviato il trial AMBITION BTK per il sistema di aterectomia Auryon.
AngioDynamics ha aumentato le previsioni per l'anno fiscale 2025, ora aspettandosi vendite nette di 285-288 milioni di dollari, una crescita delle vendite MedTech del 14-16%, un margine lordo del 53-54% e un EBITDA rettificato di 4,0-5,0 milioni di dollari. L'azienda ha ottenuto una linea di credito revolving di 25,0 milioni di dollari con J.P. Morgan per una maggiore flessibilità finanziaria.
AngioDynamics (NASDAQ: ANGO) informó sus resultados financieros del tercer trimestre del año fiscal 2025 con ventas netas pro forma de 72,0 millones de dólares, un aumento del 9,2% en comparación con el año anterior. El segmento MedTech de la compañía mostró un sólido desempeño con ventas de 31,3 millones de dólares, creciendo un 22,2%, mientras que las ventas de MedDevice alcanzaron 40,7 millones de dólares, un aumento del 0,9%.
Los aspectos destacados incluyen un margen bruto GAAP del 54,0%, una pérdida por acción de $(0,11) y un EBITDA ajustado de 1,3 millones de dólares. La compañía recibió la aprobación 510(k) de la FDA para el sistema NanoKnife para la ablación de tejido prostático e inició el ensayo AMBITION BTK para el sistema de aterectomía Auryon.
AngioDynamics aumentó su guía para el año fiscal 2025, ahora esperando ventas netas de 285-288 millones de dólares, un crecimiento de ventas de MedTech del 14-16%, un margen bruto del 53-54% y un EBITDA ajustado de 4,0-5,0 millones de dólares. La compañía aseguró una línea de crédito revolving de 25,0 millones de dólares con J.P. Morgan para mayor flexibilidad financiera.
AngioDynamics (NASDAQ: ANGO)는 2025 회계연도 3분기 재무 결과를 보고하며, 프로 포르마 순매출이 7200만 달러로 전년 대비 9.2% 증가했다고 발표했습니다. 회사의 MedTech 부문은 3130만 달러의 매출로 22.2% 성장하며 강력한 성과를 보였고, MedDevice 매출은 4070만 달러에 도달하여 0.9% 증가했습니다.
주요 하이라이트로는 GAAP 총 마진 54.0%, 주당 손실 $(0.11), 조정된 EBITDA 130만 달러가 있습니다. 회사는 전립선 조직 절제를 위한 NanoKnife 시스템에 대해 FDA 510(k) 승인을 받았으며, Auryon 동맥경화 제거 시스템에 대한 AMBITION BTK 임상을 시작했습니다.
AngioDynamics는 2025 회계연도 가이던스를 상향 조정하여 순매출이 2억 8500만~2억 8800만 달러, MedTech 매출 성장 14-16%, 총 마진 53-54%, 조정된 EBITDA 400만~500만 달러에 이를 것으로 예상하고 있습니다. 회사는 추가적인 재정적 유연성을 위해 J.P. Morgan과 2500만 달러의 회전 신용 한도를 확보했습니다.
AngioDynamics (NASDAQ: ANGO) a publié ses résultats financiers du troisième trimestre de l'exercice 2025 avec des ventes nettes pro forma de 72,0 millions de dollars, en hausse de 9,2 % par rapport à l'année précédente. Le segment MedTech de l'entreprise a montré une forte performance avec 31,3 millions de dollars de ventes, en croissance de 22,2 %, tandis que les ventes de MedDevice ont atteint 40,7 millions de dollars, en hausse de 0,9 %.
Les points clés comprennent une marge brute GAAP de 54,0 %, une perte par action de $(0,11) et un EBITDA ajusté de 1,3 million de dollars. L'entreprise a reçu l'approbation 510(k) de la FDA pour le système NanoKnife pour l'ablation des tissus prostatiques et a lancé l'essai AMBITION BTK pour le système d'athérectomie Auryon.
AngioDynamics a relevé ses prévisions pour l'exercice 2025, s'attendant désormais à des ventes nettes de 285 à 288 millions de dollars, une croissance des ventes MedTech de 14 à 16 %, une marge brute de 53 à 54 % et un EBITDA ajusté de 4,0 à 5,0 millions de dollars. L'entreprise a sécurisé une ligne de crédit revolving de 25,0 millions de dollars avec J.P. Morgan pour une flexibilité financière accrue.
AngioDynamics (NASDAQ: ANGO) hat seine finanziellen Ergebnisse für das dritte Quartal des Geschäftsjahres 2025 veröffentlicht, mit pro forma Nettoumsätzen von 72,0 Millionen Dollar, was einem Anstieg von 9,2% im Vergleich zum Vorjahr entspricht. Der MedTech-Sektor des Unternehmens zeigte eine starke Leistung mit einem Umsatz von 31,3 Millionen Dollar, was einem Wachstum von 22,2% entspricht, während die MedDevice-Umsätze 40,7 Millionen Dollar erreichten, was einem Anstieg von 0,9% entspricht.
Zu den wichtigsten Highlights gehören eine GAAP-Bruttomarge von 54,0%, ein Verlust pro Aktie von $(0,11) und ein bereinigtes EBITDA von 1,3 Millionen Dollar. Das Unternehmen erhielt die FDA 510(k)-Zulassung für das NanoKnife-System zur Ablation von Prostatagewebe und startete die AMBITION BTK-Studie für das Auryon-Atherektomiesystem.
AngioDynamics hat seine Prognose für das Geschäftsjahr 2025 angehoben und erwartet nun Nettoumsätze von 285-288 Millionen Dollar, ein Wachstum der MedTech-Umsätze von 14-16%, eine Bruttomarge von 53-54% und ein bereinigtes EBITDA von 4,0-5,0 Millionen Dollar. Das Unternehmen sicherte sich eine revolvierende Kreditlinie von 25,0 Millionen Dollar bei J.P. Morgan für zusätzliche finanzielle Flexibilität.
- MedTech segment showed strong 22.2% growth for second consecutive quarter
- Gross margin improved 290 basis points to 54.0%
- Received FDA clearance for NanoKnife System for prostate tissue ablation
- Secured $25M revolving credit line providing additional financial flexibility
- Raised FY2025 guidance across all key metrics
- Reported GAAP net loss of $4.4 million
- Negative operating cash flow of $13.2 million in Q3
- Cash position decreased from $54.1M to $44.8M quarter-over-quarter
- Med Device segment showed minimal growth of 0.9%
Insights
AngioDynamics delivered impressive third quarter results that demonstrate significant operational progress in their business transformation. The 9.2% pro forma revenue growth to
The company's strategic shift toward higher-margin products is yielding measurable results, with gross margin expanding
Management's decision to raise guidance across multiple metrics (revenue, MedTech growth, gross margin, adjusted EBITDA, and EPS) signals strengthening business momentum and improved operational efficiency. The company now projects full-year revenue of
While still reporting adjusted losses (
AngioDynamics' portfolio transformation strategy is bearing fruit with their MedTech franchise showing accelerating momentum, growing
The FDA 510(k) clearance for NanoKnife in prostate tissue ablation represents a significant commercial opportunity. The PRESERVE study results are compelling –
The Auryon atherectomy platform (
The diversified growth across multiple platforms (Auryon, AngioVac, AlphaVac, and NanoKnife) creates an increasingly resilient business model as each product line addresses distinct clinical needs with validated technologies, reducing the company's dependence on any single platform for growth.
Fiscal Year 2025 Third Quarter Highlights
|
Quarter Ended
|
Pro Forma* YoY Growth |
Pro Forma* Net Sales |
|
|
Med Tech Net Sales |
|
|
Med Device Net Sales |
|
|
-
GAAP gross margin of
54.0% -
GAAP loss per share of
$(0.11) -
Adjusted loss per share of
$(0.08) -
Adjusted EBITDA of
$1.3 million - Initiated the AMBITION BTK RCT and Registry to generate definitive clinical evidence supporting the use of the Auryon Atherectomy System in treating below the knee lesions in patients with critical limb ischemia
- Published APEX-AV trial results in JSCAI demonstrating the safety and efficacy of the AlphaVac F1885 System
- Received FDA 510(k) clearance for NanoKnife System for prostate tissue ablation
- Increasing fiscal year 2025 guidance for net sales, Med Tech net sales growth, gross margin, Adjusted EBITDA, and Adjusted EPS
*Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC and Midline product portfolios divested in February 2024, as well as the discontinued Radiofrequency and Syntrax products in February 2024. |
"We are very pleased with our third quarter performance as we continued to drive strong topline growth and adjusted EBITDA profitability. Our ability to deliver consistently strong results comes as a result of the significant transformation we have undergone over the last few years to simplify our business and focus on large, fast-growing MedTech markets," said Jim Clemmer, President and Chief Executive Officer of AngioDynamics. "To that end, we're seeing impressive momentum across our MedTech franchise, which grew over
“As we look ahead, we are well positioned to deliver profitable growth going forward. With the many catalysts we have recently achieved, including FDA clearance for our NanoKnife System for prostate tissue ablation, our portfolio is the strongest it has been. With our improved operating leverage and strong balance sheet, we can continue to prudently invest to support high impact initiatives while remaining on track to hit our fiscal year 2026 profitability targets,” continued Mr. Clemmer.
Third Quarter 2025 Financial Results
Unless otherwise noted, all financial metrics and growth rates presented below are on a pro forma basis.
Net sales for the third quarter of fiscal year 2025 were
Med Tech net sales were
Growth in the Med Tech segment for the quarter was driven by strength across all product lines, including Auryon sales of
Med Device net sales were
Gross margin for the third quarter of fiscal 2025 was
Gross margin for the Med Tech business was
The Company recorded a non-pro forma GAAP net loss of
Adjusted EBITDA in the third quarter of fiscal 2025, excluding the items shown in the non-GAAP reconciliation table below, was
In the third quarter of fiscal 2025, the Company utilized
Subsequent to the end of the third quarter of fiscal 2025, the Company announced that it secured a commitment from J.P. Morgan regarding a revolving line of credit agreement (“the revolver”), which allows the Company to draw down up to
Auryon
Initiated AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
The Company initiated the AMBITION BTK (below the knee) randomized controlled trial and registry to evaluate the effectiveness of the Auryon Atherectomy System in treating critical limb ischemia below the knee. The multicenter study will enroll up to 200 subjects across 30 sites for the RCT, plus up to 1,500 subjects in a companion registry, comparing the system in combination with standard balloon angioplasty versus angioplasty alone for below the knee lesions. This study builds on previous clinical success demonstrating the system's ability to safely treat complex below the knee cases while effectively reducing clot burden.
AlphaVac
Announced Publication of APEX-AV Trial Results in JSCAI
The Company announced the publication of APEX-AV trial results in the Journal of the Society for Cardiovascular Angiography & Interventions, validating the safety, efficacy, and efficiency of the AlphaVac F1885 System for pulmonary embolism treatment. The peer-reviewed study demonstrated a
NanoKnife
Received FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
The Company received FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation following the successful completion of the pivotal PRESERVE clinical study. The trial, which enrolled 121 patients across 17 clinical sites, met its primary effectiveness endpoint with
On January 8, 2025, the Company hosted a Virtual NanoKnife Investor Event, which provided insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the standard, function-preserving treatment for men with prostate tumors.
To access a replay of the event, visit HERE.
Fiscal Year 2025 Financial Guidance
For fiscal year 2025:
-
The Company now expects net sales to be in the range of
$285 $288 million $282 $288 million 5.3% to6.4% over fiscal 2024 pro forma revenue of$270.7 million
-
The Company now expects Med Tech net sales to grow in the range of
14% to16% , an increase from prior guidance of12% to15%
-
The Company continues to expect Med Device net sales to be flat
-
The Company now expects Gross Margin to be approximately
53% to54% , an increase from prior guidance of52% to53%
-
The Company now expects Adjusted EBITDA to be in the range of
$4.0 $5.0 million $1.0 $3.0 million $3.2 million
-
The Company now expects Adjusted loss per share in the range of
$0.31 $0.34 $0.34 $0.38 $0.45
Guidance Metric |
Guidance Action |
Current Guidance (As of Apr. 2, 2025) |
Previous Guidance (Issued on Jan. 8, 2025) |
Net Sales |
Increased |
|
|
Med Tech Net Sales Growth |
Increased |
14 - |
12 - |
Med Device Net Sales Growth |
Unchanged |
Flat (unchanged) |
Flat |
Gross Margin |
Increased |
53 - |
52 - |
Adjusted EBITDA |
Increased |
|
|
Adjusted EPS |
Increased |
( |
( |
Conference Call
The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).
This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available, until Wednesday, April 09, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13752371.
Virtual Cardiovascular Investor Event
AngioDynamics will host a virtual cardiovascular investor event immediately following the Company’s Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 9:00am ET. The Company will provide investors a deeper dive into the cardiovascular technology portfolio and strategic vision.
Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=cedf6b19b1
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported pro forma results, adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
1 https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/ |
|
2 Cheng JY. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) in Perspective. J Clin Med Res. 2013;5(4):266-268. doi:10.4021/jocmr1395w |
|
3 Data on file. |
| ANGIODYNAMICS, INC. AND SUBSIDIARIES | |||||||||||||||||||||||
CONSOLIDATED INCOME STATEMENTS |
|||||||||||||||||||||||
(in thousands, except per share data) |
|||||||||||||||||||||||
|
Three Months Ended |
|
Three Months Ended |
||||||||||||||||||||
|
Actual (1) |
|
Pro Forma
|
|
Pro Forma |
|
As Reported (1) |
|
Pro Forma
|
|
Pro Forma |
||||||||||||
|
Feb 28, 2025 |
|
Feb 28, 2025 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 29, 2024 |
|
Feb 29, 2024 |
||||||||||||
|
|
|
(unaudited) |
|
|
|
|
|
(unaudited) |
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net sales |
$ |
72,004 |
|
|
|
9 |
|
|
$ |
72,013 |
|
|
$ |
75,182 |
|
|
|
(9,211 |
) |
|
$ |
65,971 |
|
Cost of sales (exclusive of intangible amortization) |
|
33,147 |
|
|
|
6 |
|
|
|
33,153 |
|
|
|
39,321 |
|
|
|
(7,038 |
) |
|
|
32,283 |
|
Gross profit |
|
38,857 |
|
|
|
3 |
|
|
|
38,860 |
|
|
|
35,861 |
|
|
|
(2,173 |
) |
|
|
33,688 |
|
% of net sales |
|
54.0 |
% |
|
|
|
|
54.0 |
% |
|
|
47.7 |
% |
|
|
|
|
51.1 |
% |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Research and development |
|
6,913 |
|
|
|
— |
|
|
|
6,913 |
|
|
|
8,189 |
|
|
|
(117 |
) |
|
|
8,072 |
|
Sales and marketing |
|
25,504 |
|
|
|
— |
|
|
|
25,504 |
|
|
|
25,405 |
|
|
|
(1,758 |
) |
|
|
23,647 |
|
General and administrative |
|
10,490 |
|
|
|
— |
|
|
|
10,490 |
|
|
|
10,578 |
|
|
|
22 |
|
|
|
10,600 |
|
Amortization of intangibles |
|
2,598 |
|
|
|
— |
|
|
|
2,598 |
|
|
|
3,287 |
|
|
|
(643 |
) |
|
|
2,644 |
|
Goodwill impairment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
159,476 |
|
|
|
— |
|
|
|
159,476 |
|
Change in fair value of contingent consideration |
|
40 |
|
|
|
— |
|
|
|
40 |
|
|
|
112 |
|
|
|
— |
|
|
|
112 |
|
Acquisition, restructuring and other items, net |
|
3,286 |
|
|
|
(3 |
) |
|
|
3,283 |
|
|
|
35,367 |
|
|
|
(6,266 |
) |
|
|
29,101 |
|
Total operating expenses |
|
48,831 |
|
|
|
(3 |
) |
|
|
48,828 |
|
|
|
242,414 |
|
|
|
(8,762 |
) |
|
|
233,652 |
|
Gain on sale of assets |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6,657 |
|
|
|
(6,657 |
) |
|
|
— |
|
Operating loss |
|
(9,974 |
) |
|
|
6 |
|
|
|
(9,968 |
) |
|
|
(199,896 |
) |
|
|
(68 |
) |
|
|
(199,964 |
) |
Interest income, net |
|
135 |
|
|
|
— |
|
|
|
135 |
|
|
|
394 |
|
|
|
— |
|
|
|
394 |
|
Other income (expense), net |
|
5,430 |
|
|
|
(5,500 |
) |
|
|
(70 |
) |
|
|
(238 |
) |
|
|
— |
|
|
|
(238 |
) |
Total other income, net |
|
5,565 |
|
|
|
(5,500 |
) |
|
|
65 |
|
|
|
156 |
|
|
|
— |
|
|
|
156 |
|
Loss before income tax benefit |
|
(4,409 |
) |
|
|
(5,494 |
) |
|
|
(9,903 |
) |
|
|
(199,740 |
) |
|
|
(68 |
) |
|
|
(199,808 |
) |
Income tax expense (benefit) |
|
(2 |
) |
|
|
— |
|
|
|
(2 |
) |
|
|
(12,004 |
) |
|
|
— |
|
|
|
(12,004 |
) |
Net loss |
$ |
(4,407 |
) |
|
$ |
(5,494 |
) |
|
$ |
(9,901 |
) |
|
$ |
(187,736 |
) |
|
$ |
(68 |
) |
|
$ |
(187,804 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Loss per share |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Basic |
$ |
(0.11 |
) |
|
|
|
$ |
(0.24 |
) |
|
$ |
(4.67 |
) |
|
|
|
$ |
(4.67 |
) |
||||
Diluted |
$ |
(0.11 |
) |
|
|
|
$ |
(0.24 |
) |
|
$ |
(4.67 |
) |
|
|
|
$ |
(4.67 |
) |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Basic |
|
40,853 |
|
|
|
|
|
40,853 |
|
|
|
40,234 |
|
|
|
|
|
40,234 |
|
||||
Diluted |
|
40,853 |
|
|
|
|
|
40,853 |
|
|
|
40,234 |
|
|
|
|
|
40,234 |
|
||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2025 and February 29, 2024. |
|
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses. |
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES |
|||||||||||||||||||||||
CONSOLIDATED INCOME STATEMENTS |
|||||||||||||||||||||||
(in thousands, except per share data) |
|||||||||||||||||||||||
|
Nine Months Ended |
|
Nine Months Ended |
||||||||||||||||||||
|
Actual (1) |
|
Pro Forma
|
|
Pro Forma |
|
As Reported (1) |
|
Pro Forma
|
|
Pro Forma |
||||||||||||
|
Feb 28, 2025 |
|
Feb 28, 2025 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 29, 2024 |
|
Feb 29, 2024 |
||||||||||||
|
|
|
(unaudited) |
|
|
|
|
|
(unaudited) |
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net sales |
$ |
212,340 |
|
|
|
188 |
|
|
$ |
212,528 |
|
|
$ |
232,934 |
|
|
|
(33,336 |
) |
|
$ |
199,598 |
|
Cost of sales (exclusive of intangible amortization) |
|
96,853 |
|
|
|
155 |
|
|
|
97,008 |
|
|
|
116,751 |
|
|
|
(24,121 |
) |
|
|
92,630 |
|
Gross profit |
|
115,487 |
|
|
|
33 |
|
|
|
115,520 |
|
|
|
116,183 |
|
|
|
(9,215 |
) |
|
|
106,968 |
|
% of net sales |
|
54.4 |
% |
|
|
|
|
54.4 |
% |
|
|
49.9 |
% |
|
|
|
|
53.6 |
% |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Research and development |
|
19,632 |
|
|
|
— |
|
|
|
19,632 |
|
|
|
24,788 |
|
|
|
(647 |
) |
|
|
24,141 |
|
Sales and marketing |
|
76,698 |
|
|
|
— |
|
|
|
76,698 |
|
|
|
78,237 |
|
|
|
(4,714 |
) |
|
|
73,523 |
|
General and administrative |
|
31,856 |
|
|
|
— |
|
|
|
31,856 |
|
|
|
30,723 |
|
|
|
(52 |
) |
|
|
30,671 |
|
Amortization of intangibles |
|
7,730 |
|
|
|
— |
|
|
|
7,730 |
|
|
|
10,474 |
|
|
|
(2,571 |
) |
|
|
7,903 |
|
Goodwill impairment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
159,476 |
|
|
|
— |
|
|
|
159,476 |
|
Change in fair value of contingent consideration |
|
272 |
|
|
|
— |
|
|
|
272 |
|
|
|
203 |
|
|
|
— |
|
|
|
203 |
|
Acquisition, restructuring and other items, net |
|
13,465 |
|
|
|
161 |
|
|
|
13,626 |
|
|
|
44,767 |
|
|
|
(6,394 |
) |
|
|
38,373 |
|
Total operating expenses |
|
149,653 |
|
|
|
161 |
|
|
|
149,814 |
|
|
|
348,668 |
|
|
|
(14,378 |
) |
|
|
334,290 |
|
Gain on sale of assets |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
54,499 |
|
|
|
(54,499 |
) |
|
|
— |
|
Operating loss |
|
(34,166 |
) |
|
|
(128 |
) |
|
|
(34,294 |
) |
|
|
(177,986 |
) |
|
|
(49,336 |
) |
|
|
(227,322 |
) |
Interest income, net |
|
975 |
|
|
|
— |
|
|
|
975 |
|
|
|
1,047 |
|
|
|
— |
|
|
|
1,047 |
|
Other income (expense), net |
|
5,269 |
|
|
|
(5,500 |
) |
|
|
(231 |
) |
|
|
(558 |
) |
|
|
— |
|
|
|
(558 |
) |
Total other income, net |
|
6,244 |
|
|
|
(5,500 |
) |
|
|
744 |
|
|
|
489 |
|
|
|
— |
|
|
|
489 |
|
Loss before income tax benefit |
|
(27,922 |
) |
|
|
(5,628 |
) |
|
|
(33,550 |
) |
|
|
(177,497 |
) |
|
|
(49,336 |
) |
|
|
(226,833 |
) |
Income tax expense (benefit) |
|
21 |
|
|
|
— |
|
|
|
21 |
|
|
|
(6,597 |
) |
|
|
— |
|
|
|
(6,597 |
) |
Net loss |
$ |
(27,943 |
) |
|
$ |
(5,628 |
) |
|
$ |
(33,571 |
) |
|
$ |
(170,900 |
) |
|
$ |
(49,336 |
) |
|
$ |
(220,236 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Loss per share |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Basic |
$ |
(0.68 |
) |
|
|
|
$ |
(0.82 |
) |
|
$ |
(4.26 |
) |
|
|
|
$ |
(5.49 |
) |
||||
Diluted |
$ |
(0.68 |
) |
|
|
|
$ |
(0.82 |
) |
|
$ |
(4.26 |
) |
|
|
|
$ |
(5.49 |
) |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Basic |
|
40,809 |
|
|
|
|
|
40,809 |
|
|
|
40,098 |
|
|
|
|
|
40,098 |
|
||||
Diluted |
|
40,809 |
|
|
|
|
|
40,809 |
|
|
|
40,098 |
|
|
|
|
|
40,098 |
|
||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2025 and February 29, 2024. |
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses. |
ANGIODYNAMICS, INC. AND SUBSIDIARIES |
|||||||||||||||
GAAP TO NON-GAAP RECONCILIATION |
|||||||||||||||
(in thousands, except per share data) |
|||||||||||||||
Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss): |
|
|
|
|
|||||||||||
|
|
|
|
|
|
||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
||||||||
|
(unaudited) |
|
(unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Net loss |
$ |
(4,407 |
) |
|
$ |
(187,736 |
) |
|
$ |
(27,943 |
) |
|
$ |
(170,900 |
) |
|
|
|
|
|
|
|
|
||||||||
Amortization of intangibles |
|
2,598 |
|
|
|
3,287 |
|
|
|
7,730 |
|
|
|
10,474 |
|
Change in fair value of contingent consideration |
|
40 |
|
|
|
112 |
|
|
|
272 |
|
|
|
203 |
|
Acquisition, restructuring and other items, net (1) |
|
3,286 |
|
|
|
35,367 |
|
|
|
13,465 |
|
|
|
44,767 |
|
Goodwill impairment |
|
— |
|
|
|
159,476 |
|
|
|
— |
|
|
|
159,476 |
|
Gain on sale of assets |
|
— |
|
|
|
(6,657 |
) |
|
|
— |
|
|
|
(54,499 |
) |
Tax effect of non-GAAP items (2) |
|
(350 |
) |
|
|
(10,128 |
) |
|
|
1,506 |
|
|
|
(2,670 |
) |
Adjusted net income (loss) |
$ |
1,167 |
|
|
$ |
(6,279 |
) |
|
$ |
(4,970 |
) |
|
$ |
(13,149 |
) |
|
|
|
|
|
|
|
|
||||||||
Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Income (Loss) Per Share: |
|||||||||||||||
|
|
|
|
|
|
||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
||||||||
|
(unaudited) |
|
(unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Diluted loss per share |
$ |
(0.11 |
) |
|
$ |
(4.67 |
) |
|
$ |
(0.68 |
) |
|
$ |
(4.26 |
) |
|
|
|
|
|
|
|
|
||||||||
Amortization of intangibles |
|
0.06 |
|
|
|
0.08 |
|
|
|
0.19 |
|
|
|
0.26 |
|
Change in fair value of contingent consideration |
|
0.01 |
|
|
|
0.00 |
|
|
|
0.01 |
|
|
|
0.01 |
|
Acquisition, restructuring and other items, net (1) |
|
0.08 |
|
|
|
0.89 |
|
|
|
0.32 |
|
|
|
1.11 |
|
Goodwill impairment |
|
— |
|
|
|
3.96 |
|
|
|
— |
|
|
|
3.98 |
|
Gain on sale of assets |
|
— |
|
|
|
(0.17 |
) |
|
|
— |
|
|
|
(1.36 |
) |
Tax effect of non-GAAP items (2) |
|
(0.01 |
) |
|
|
(0.25 |
) |
|
|
0.04 |
|
|
|
(0.07 |
) |
Adjusted diluted income (loss) per share |
$ |
0.03 |
|
|
$ |
(0.16 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.33 |
) |
|
|
|
|
|
|
|
|
||||||||
Adjusted diluted sharecount (3) |
|
42,091 |
|
|
|
40,234 |
|
|
|
40,809 |
|
|
|
40,098 |
|
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. |
(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's |
(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss. |
ANGIODYNAMICS, INC. AND SUBSIDIARIES |
|||||||||||||||
GAAP TO NON-GAAP RECONCILIATION (Continued) |
|||||||||||||||
(in thousands, except per share data) |
|||||||||||||||
Reconciliation of Net Loss to Adjusted EBITDA: |
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
||||||||
|
(unaudited) |
|
(unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Net loss |
$ |
(4,407 |
) |
|
$ |
(187,736 |
) |
|
$ |
(27,943 |
) |
|
$ |
(170,900 |
) |
|
|
|
|
|
|
|
|
||||||||
Income tax expense (benefit) |
|
(2 |
) |
|
|
(12,004 |
) |
|
|
21 |
|
|
|
(6,597 |
) |
Interest income, net |
|
(135 |
) |
|
|
(394 |
) |
|
|
(975 |
) |
|
|
(1,047 |
) |
Depreciation and amortization |
|
6,319 |
|
|
|
7,522 |
|
|
|
19,967 |
|
|
|
20,895 |
|
Goodwill impairment |
|
— |
|
|
|
159,476 |
|
|
|
— |
|
|
|
159,476 |
|
Change in fair value of contingent consideration |
|
40 |
|
|
|
112 |
|
|
|
272 |
|
|
|
203 |
|
Stock based compensation |
|
2,398 |
|
|
|
2,612 |
|
|
|
8,131 |
|
|
|
8,633 |
|
Acquisition, restructuring and other items, net (1) |
|
2,623 |
|
|
|
34,232 |
|
|
|
10,239 |
|
|
|
43,632 |
|
Gain on sale of assets |
|
— |
|
|
|
(6,657 |
) |
|
|
— |
|
|
|
(54,499 |
) |
Adjusted EBITDA |
$ |
6,836 |
|
|
$ |
(2,837 |
) |
|
$ |
9,712 |
|
|
$ |
(204 |
) |
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. |
ANGIODYNAMICS, INC. AND SUBSIDIARIES |
|||||||||||||||
GAAP TO NON-GAAP RECONCILIATION |
|||||||||||||||
(in thousands, except per share data) |
|||||||||||||||
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted Net Loss: |
|
|
|
|
|||||||||||
|
Pro Forma |
|
Pro Forma |
||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
||||||||
|
(unaudited) |
|
(unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Pro forma net loss |
$ |
(9,901 |
) |
|
$ |
(187,804 |
) |
|
$ |
(33,571 |
) |
|
$ |
(220,236 |
) |
|
|
|
|
|
|
|
|
||||||||
Amortization of intangibles |
|
2,598 |
|
|
|
2,644 |
|
|
|
7,730 |
|
|
|
7,903 |
|
Change in fair value of contingent consideration |
|
40 |
|
|
|
112 |
|
|
|
272 |
|
|
|
203 |
|
Acquisition, restructuring and other items, net (1) |
|
3,283 |
|
|
|
29,101 |
|
|
|
13,626 |
|
|
|
38,373 |
|
Goodwill impairment |
|
— |
|
|
|
159,476 |
|
|
|
— |
|
|
|
159,476 |
|
Tax effect of non-GAAP items (2) |
|
914 |
|
|
|
(10,055 |
) |
|
|
2,763 |
|
|
|
(1,795 |
) |
Adjusted pro forma net loss |
$ |
(3,066 |
) |
|
$ |
(6,526 |
) |
|
$ |
(9,180 |
) |
|
$ |
(16,076 |
) |
|
|
|
|
|
|
|
|
||||||||
Reconciliation of Pro Forma Diluted Loss Per Share to Pro Forma Adjusted Diluted Loss Per Share: |
|||||||||||||||
|
Pro Forma |
|
Pro Forma |
||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
||||||||
|
(unaudited) |
|
(unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Pro forma diluted loss per share |
$ |
(0.24 |
) |
|
$ |
(4.67 |
) |
|
$ |
(0.82 |
) |
|
$ |
(5.49 |
) |
|
|
|
|
|
|
|
|
||||||||
Amortization of intangibles |
|
0.06 |
|
|
|
0.07 |
|
|
|
0.19 |
|
|
|
0.20 |
|
Change in fair value of contingent consideration |
|
0.01 |
|
|
|
0.01 |
|
|
|
0.01 |
|
|
|
0.01 |
|
Acquisition, restructuring and other items, net (1) |
|
0.07 |
|
|
|
0.72 |
|
|
|
0.33 |
|
|
|
0.94 |
|
Goodwill impairment |
|
— |
|
|
|
3.96 |
|
|
|
— |
|
|
|
3.98 |
|
Tax effect of non-GAAP items (2) |
|
0.02 |
|
|
|
(0.25 |
) |
|
|
0.07 |
|
|
|
(0.04 |
) |
Adjusted pro forma diluted loss per share |
$ |
(0.08 |
) |
|
$ |
(0.16 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.40 |
) |
|
|
|
|
|
|
|
|
||||||||
Adjusted diluted sharecount (3) |
|
40,853 |
|
|
|
40,234 |
|
|
|
40,809 |
|
|
|
40,098 |
|
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. |
(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's |
(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss. |
ANGIODYNAMICS, INC. AND SUBSIDIARIES |
|||||||||||||||
GAAP TO NON-GAAP RECONCILIATION (Continued) |
|||||||||||||||
(in thousands, except per share data) |
|||||||||||||||
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted EBITDA: |
|
|
|
|
|
|
|||||||||
|
Pro Forma |
|
Pro Forma |
||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
||||||||
|
(unaudited) |
|
(unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Pro forma net loss |
$ |
(9,901 |
) |
|
$ |
(187,804 |
) |
|
$ |
(33,571 |
) |
|
$ |
(220,236 |
) |
|
|
|
|
|
|
|
|
||||||||
Income tax expense (benefit) |
|
(2 |
) |
|
|
(12,004 |
) |
|
|
21 |
|
|
|
(6,597 |
) |
Interest income, net |
|
(135 |
) |
|
|
(394 |
) |
|
|
(975 |
) |
|
|
(1,047 |
) |
Depreciation and amortization |
|
6,319 |
|
|
|
6,861 |
|
|
|
19,967 |
|
|
|
18,234 |
|
Goodwill impairment |
|
— |
|
|
|
159,476 |
|
|
|
— |
|
|
|
159,476 |
|
Change in fair value of contingent consideration |
|
40 |
|
|
|
112 |
|
|
|
272 |
|
|
|
203 |
|
Stock based compensation |
|
2,398 |
|
|
|
2,142 |
|
|
|
8,131 |
|
|
|
8,000 |
|
Acquisition, restructuring and other items, net (1) |
|
2,620 |
|
|
|
27,966 |
|
|
|
10,400 |
|
|
|
37,238 |
|
Adjusted EBITDA |
$ |
1,339 |
|
|
$ |
(3,645 |
) |
|
$ |
4,245 |
|
|
$ |
(4,729 |
) |
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. |
ANGIODYNAMICS, INC. AND SUBSIDIARIES |
|||||||||||||||
ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET DETAIL |
|||||||||||||||
(in thousands) |
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
(in thousands) |
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
||||||||
Legal (1) |
$ |
— |
|
|
$ |
23,314 |
|
|
$ |
406 |
|
|
$ |
30,453 |
|
Mergers and acquisitions |
|
— |
|
|
|
147 |
|
|
|
737 |
|
|
|
399 |
|
Plant closure (2) |
|
3,130 |
|
|
|
5,426 |
|
|
|
11,820 |
|
|
|
6,115 |
|
Intangible and other asset impairment |
|
— |
|
|
|
6,260 |
|
|
|
— |
|
|
|
6,260 |
|
Transition service agreement (3) |
|
(463 |
) |
|
|
(333 |
) |
|
|
(1,424 |
) |
|
|
(655 |
) |
Manufacturing relocation (4) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
587 |
|
Other (5) |
|
619 |
|
|
|
553 |
|
|
|
1,926 |
|
|
|
1,608 |
|
Total |
$ |
3,286 |
|
|
$ |
35,367 |
|
|
$ |
13,465 |
|
|
$ |
44,767 |
|
(1) Legal expenses related to litigation that is outside the normal course of business. For the three and nine months ended February 29, 2024, a |
(2) Plant closure expenses, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024. |
(3) Transition services agreements that were entered into with Merit and Spectrum. |
(4) Expenses to relocate certain manufacturing lines out of |
(5) Included in the |
| ANGIODYNAMICS, INC. AND SUBSIDIARIES | ||||||||||||||||||||||||||||
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY |
||||||||||||||||||||||||||||
(in thousands) |
||||||||||||||||||||||||||||
|
Three Months Ended |
|
Three Months Ended |
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Actual (1) |
Pro Forma
|
Pro
|
|
As
|
Pro Forma
|
Pro
|
|
Actual |
|
Pro
|
|||||||||||||||||
|
Feb 28,
|
Feb 28,
|
Feb 28,
|
|
Feb 29,
|
Feb 29,
|
Feb 29,
|
|
%
|
Currency
|
Constant
|
|
%
|
Currency
|
Constant
|
|||||||||||||
|
|
(unaudited) |
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|||||||||||||
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Med Tech |
$ |
31,341 |
$ |
— |
$ |
31,341 |
|
$ |
25,844 |
$ |
(190 |
) |
$ |
25,654 |
|
21.3 |
% |
|
|
|
22.2 |
% |
|
|
||||
Med Device |
|
40,663 |
|
9 |
|
40,672 |
|
|
49,338 |
|
(9,021 |
) |
|
40,317 |
|
(17.6 |
)% |
|
|
|
0.9 |
% |
|
|
||||
|
$ |
72,004 |
$ |
9 |
$ |
72,013 |
|
$ |
75,182 |
$ |
(9,211 |
) |
$ |
65,971 |
|
(4.2 |
)% |
0.2 |
% |
(4.0 |
)% |
|
9.2 |
% |
0.2 |
% |
9.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
$ |
61,340 |
$ |
4 |
$ |
61,344 |
|
$ |
62,342 |
$ |
(6,521 |
) |
$ |
55,821 |
|
(1.6 |
)% |
|
|
|
9.9 |
% |
|
|
||||
International |
|
10,664 |
|
5 |
|
10,669 |
|
|
12,840 |
|
(2,690 |
) |
|
10,150 |
|
(16.9 |
)% |
1.1 |
% |
(15.8 |
)% |
|
5.1 |
% |
|
|
||
|
$ |
72,004 |
$ |
9 |
$ |
72,013 |
|
$ |
75,182 |
$ |
(9,211 |
) |
$ |
65,971 |
|
(4.2 |
)% |
0.2 |
% |
(4.0 |
)% |
|
9.2 |
% |
0.2 |
% |
9.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2025 and February 29, 2024. |
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses. |
GROSS PROFIT BY PRODUCT CATEGORY |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
(in thousands) |
||||||||||||||||||||||||
|
Three Months Ended |
|
Three Months Ended |
|
|
|
|
|||||||||||||||||
|
Actual (1) |
Pro Forma
|
Pro
|
|
As Reported (1) |
Pro Forma
|
Pro
|
|
Actual |
|
Pro
|
|||||||||||||
|
Feb 28,
|
Feb 28,
|
Feb 28,
|
|
Feb 29,
|
Feb 29,
|
Feb 29,
|
|
% Change |
|
% Change |
|||||||||||||
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|||||||||||||||||
Med Tech |
$ |
19,588 |
|
$ |
— |
$ |
19,588 |
|
|
$ |
15,857 |
|
$ |
(83 |
) |
$ |
15,774 |
|
|
23.5 |
% |
|
24.2 |
% |
Gross profit % of sales |
|
62.5 |
% |
|
|
62.5 |
% |
|
|
61.4 |
% |
|
|
61.5 |
% |
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Med Device |
$ |
19,269 |
|
$ |
3 |
$ |
19,272 |
|
|
$ |
20,004 |
|
$ |
(2,090 |
) |
$ |
17,914 |
|
|
(3.7 |
)% |
|
7.6 |
% |
Gross profit % of sales |
|
47.4 |
% |
|
|
47.4 |
% |
|
|
40.5 |
% |
|
|
44.4 |
% |
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
$ |
38,857 |
|
$ |
3 |
$ |
38,860 |
|
|
$ |
35,861 |
|
$ |
(2,173 |
) |
$ |
33,688 |
|
|
8.4 |
% |
|
15.4 |
% |
Gross profit % of sales |
|
54.0 |
% |
|
|
54.0 |
% |
|
|
47.7 |
% |
|
|
51.1 |
% |
|
|
|
|
|||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2025 and February 29, 2024. |
|
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses. |
ANGIODYNAMICS, INC. AND SUBSIDIARIES |
||||||||||||||||||||||||||||
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY |
||||||||||||||||||||||||||||
(in thousands) |
||||||||||||||||||||||||||||
|
Nine Months Ended |
|
Nine Months Ended |
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Actual (1) |
Pro Forma
|
Pro
|
|
As
|
Pro Forma
|
Pro
|
|
Actual |
|
Pro
|
|||||||||||||||||
|
Feb 28,
|
Feb 28,
|
Feb 28,
|
|
Feb 29,
|
Feb 29,
|
Feb 29,
|
|
%
|
Currency
|
Constant
|
|
%
|
Currency
|
Constant
|
|||||||||||||
|
|
(unaudited) |
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|||||||||||||
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Med Tech |
$ |
90,863 |
$ |
— |
$ |
90,863 |
|
$ |
77,068 |
$ |
(443 |
) |
$ |
76,625 |
|
17.9 |
% |
|
|
|
18.6 |
% |
|
|
||||
Med Device |
|
121,477 |
|
188 |
|
121,665 |
|
|
155,866 |
|
(32,893 |
) |
|
122,973 |
|
(22.1 |
)% |
|
|
|
(1.1 |
)% |
|
|
||||
|
$ |
212,340 |
$ |
188 |
$ |
212,528 |
|
$ |
232,934 |
$ |
(33,336 |
) |
$ |
199,598 |
|
(8.8 |
)% |
0.0 |
% |
(8.8 |
)% |
|
6.5 |
% |
0.1 |
% |
6.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
$ |
183,499 |
$ |
14 |
$ |
183,513 |
|
$ |
190,743 |
$ |
(23,098 |
) |
$ |
167,645 |
|
(3.8 |
)% |
|
|
|
9.5 |
% |
|
|
||||
International |
|
28,841 |
|
174 |
|
29,015 |
|
|
42,191 |
|
(10,238 |
) |
|
31,953 |
|
(31.6 |
)% |
0.4 |
% |
(31.2 |
)% |
|
(9.2 |
)% |
|
|
||
|
$ |
212,340 |
$ |
188 |
$ |
212,528 |
|
$ |
232,934 |
$ |
(33,336 |
) |
$ |
199,598 |
|
(8.8 |
)% |
0.0 |
% |
(8.8 |
)% |
|
6.5 |
% |
0.1 |
% |
6.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2025 and February 29, 2024. |
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses. |
GROSS PROFIT BY PRODUCT CATEGORY |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
(in thousands) |
||||||||||||||||||||||||
|
Nine Months Ended |
|
Nine Months Ended |
|
|
|
|
|||||||||||||||||
|
Actual (1) |
Pro Forma
|
Pro
|
|
As Reported (1) |
Pro Forma
|
Pro
|
|
Actual |
|
Pro
|
|||||||||||||
|
Feb 28,
|
Feb 28,
|
Feb 28,
|
|
Feb 29,
|
Feb 29,
|
Feb 29,
|
|
% Change |
|
% Change |
|||||||||||||
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|||||||||||||||||
Med Tech |
$ |
57,398 |
|
$ |
— |
$ |
57,398 |
|
|
$ |
48,400 |
|
$ |
(155 |
) |
$ |
48,245 |
|
|
18.6 |
% |
|
19.0 |
% |
Gross profit % of sales |
|
63.2 |
% |
|
|
63.2 |
% |
|
|
62.8 |
% |
|
|
63.0 |
% |
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Med Device |
$ |
58,089 |
|
|
33 |
$ |
58,122 |
|
|
$ |
67,783 |
|
$ |
(9,060 |
) |
$ |
58,723 |
|
|
(14.3 |
)% |
|
(1.0 |
)% |
Gross profit % of sales |
|
47.8 |
% |
|
|
47.8 |
% |
|
|
43.5 |
% |
|
|
47.7 |
% |
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
$ |
115,487 |
|
$ |
33 |
$ |
115,520 |
|
|
$ |
116,183 |
|
$ |
(9,215 |
) |
$ |
106,968 |
|
|
(0.6 |
)% |
|
8.0 |
% |
Gross profit % of sales |
|
54.4 |
% |
|
|
54.4 |
% |
|
|
49.9 |
% |
|
|
53.6 |
% |
|
|
|
|
|||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2025 and 2024. |
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses. |
| ANGIODYNAMICS, INC. AND SUBSIDIARIES | |||||
CONSOLIDATED BALANCE SHEETS |
|||||
(in thousands) |
|||||
|
Feb 28, 2025 |
|
May 31, 2024 |
||
|
(unaudited) |
|
(audited) |
||
Assets |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
44,760 |
|
$ |
76,056 |
Accounts receivable, net |
|
43,468 |
|
|
43,610 |
Inventories |
|
63,105 |
|
|
60,616 |
Earn-out receivable |
|
5,500 |
|
|
— |
Prepaid expenses and other |
|
15,440 |
|
|
12,971 |
Total current assets |
|
172,273 |
|
|
193,253 |
Property, plant and equipment, net |
|
32,530 |
|
|
35,666 |
Other assets |
|
9,681 |
|
|
11,369 |
Intangible assets, net |
|
70,931 |
|
|
77,383 |
Total assets |
$ |
285,415 |
|
$ |
317,671 |
Liabilities and stockholders' equity |
|
|
|
||
Current liabilities: |
|
|
|
||
Accounts payable |
$ |
30,265 |
|
$ |
37,751 |
Accrued liabilities |
|
36,949 |
|
|
41,098 |
Current portion of contingent consideration |
|
5,000 |
|
|
4,728 |
Other current liabilities |
|
5,757 |
|
|
7,578 |
Total current liabilities |
|
77,971 |
|
|
91,155 |
Deferred income taxes |
|
4,203 |
|
|
4,852 |
Other long-term liabilities |
|
17,371 |
|
|
16,078 |
Total liabilities |
|
99,545 |
|
|
112,085 |
Stockholders' equity |
|
185,870 |
|
|
205,586 |
Total Liabilities and Stockholders' Equity |
$ |
285,415 |
|
$ |
317,671 |
| ANGIODYNAMICS, INC. AND SUBSIDIARIES | |||||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||||||||||
(in thousands) |
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
Feb 28, 2025 |
|
Feb 29, 2024 |
|
Feb 28, 2025 |
|
Feb 29, 2024 |
||||||||
|
(unaudited) |
|
(unaudited) |
||||||||||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
||||||||
Net loss |
$ |
(4,407 |
) |
|
$ |
(187,736 |
) |
|
$ |
(27,943 |
) |
|
$ |
(170,900 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
||||||||
Depreciation and amortization |
|
6,319 |
|
|
|
7,522 |
|
|
|
19,967 |
|
|
|
20,895 |
|
Non-cash lease expense |
|
503 |
|
|
|
484 |
|
|
|
1,496 |
|
|
|
1,441 |
|
Stock based compensation |
|
2,398 |
|
|
|
2,612 |
|
|
|
8,131 |
|
|
|
8,633 |
|
Gain on disposal of assets |
|
— |
|
|
|
(6,657 |
) |
|
|
— |
|
|
|
(54,499 |
) |
Transaction costs for disposition |
|
— |
|
|
|
(2,657 |
) |
|
|
— |
|
|
|
(5,084 |
) |
Change in fair value of contingent consideration |
|
40 |
|
|
|
112 |
|
|
|
272 |
|
|
|
203 |
|
Impairment loss on indefinite-lived intangible assets (1) |
|
— |
|
|
|
159,476 |
|
|
|
— |
|
|
|
159,476 |
|
Deferred income taxes |
|
(207 |
) |
|
|
(12,094 |
) |
|
|
(795 |
) |
|
|
(7,143 |
) |
Change in accounts receivable allowances |
|
142 |
|
|
|
458 |
|
|
|
530 |
|
|
|
1,007 |
|
Fixed and intangible asset impairments and disposals |
|
38 |
|
|
|
6,845 |
|
|
|
97 |
|
|
|
7,084 |
|
Write-off of other assets |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
869 |
|
Other |
|
30 |
|
|
|
299 |
|
|
|
149 |
|
|
|
161 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
||||||||
Accounts receivable |
|
(474 |
) |
|
|
1,668 |
|
|
|
(424 |
) |
|
|
2,345 |
|
Inventories |
|
2,810 |
|
|
|
2,019 |
|
|
|
(2,493 |
) |
|
|
(6,825 |
) |
Prepaid expenses and other |
|
(9,387 |
) |
|
|
(2,587 |
) |
|
|
(9,459 |
) |
|
|
(7,566 |
) |
Accounts payable, accrued and other liabilities |
|
(10,964 |
) |
|
|
17,710 |
|
|
|
(18,467 |
) |
|
|
16,744 |
|
Net cash used in operating activities |
|
(13,159 |
) |
|
|
(12,526 |
) |
|
|
(28,939 |
) |
|
|
(33,159 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
|
||||||||
Additions to property, plant and equipment |
|
(1,798 |
) |
|
|
(607 |
) |
|
|
(3,687 |
) |
|
|
(1,952 |
) |
Additions to placement and evaluation units |
|
(1,391 |
) |
|
|
(1,239 |
) |
|
|
(3,868 |
) |
|
|
(3,245 |
) |
Acquisition of intangibles |
|
— |
|
|
|
(3,250 |
) |
|
|
— |
|
|
|
(3,250 |
) |
Proceeds from sale of assets |
|
— |
|
|
|
34,500 |
|
|
|
— |
|
|
|
134,500 |
|
Net cash (used in) provided by investing activities |
|
(3,189 |
) |
|
|
29,404 |
|
|
|
(7,555 |
) |
|
|
126,053 |
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
||||||||
Repayment of long-term debt |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(50,000 |
) |
Payment of acquisition related contingent consideration |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(10,000 |
) |
Principal payments on finance arrangement |
|
(58 |
) |
|
|
— |
|
|
|
(58 |
) |
|
|
— |
|
Proceeds from finance arrangement |
|
6,310 |
|
|
|
— |
|
|
|
6,310 |
|
|
|
— |
|
Repurchase of common stock |
|
— |
|
|
|
— |
|
|
|
(1,670 |
) |
|
|
— |
|
Proceeds from exercise of stock options and employee stock purchase plan |
|
895 |
|
|
|
694 |
|
|
|
933 |
|
|
|
752 |
|
Net cash provided by (used) in financing activities |
|
7,147 |
|
|
|
694 |
|
|
|
5,515 |
|
|
|
(59,248 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
(128 |
) |
|
|
(17 |
) |
|
|
(317 |
) |
|
|
185 |
|
Increase (decrease) in cash and cash equivalents |
|
(9,329 |
) |
|
|
17,555 |
|
|
|
(31,296 |
) |
|
|
33,831 |
|
Cash and cash equivalents at beginning of period |
|
54,089 |
|
|
|
60,896 |
|
|
|
76,056 |
|
|
|
44,620 |
|
Cash and cash equivalents at end of period |
$ |
44,760 |
|
|
$ |
78,451 |
|
|
$ |
44,760 |
|
|
$ |
78,451 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402329970/en/
Investors:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
strowbridge@angiodynamics.com
Media:
Saleem Cheeks
Vice President, Communications
518-795-1174
scheeks@angiodynamics.com
Source: AngioDynamics, Inc.
FAQ
What were AngioDynamics (ANGO) Q3 FY2025 MedTech sales and growth rate?
What is the new FY2025 revenue guidance for AngioDynamics (ANGO)?
What was the outcome of ANGO's PRESERVE clinical study for NanoKnife?
How much cash does AngioDynamics (ANGO) have as of Q3 FY2025?
What are the key growth drivers for ANGO's MedTech segment in Q3 FY2025?
